Science and Technology


Over the last 3 years, various epidemiological studies have shown the existence of a strong linkage between obesity, diabetes and development of cancer.

  • Epidemiological studies have demonstrated that both obesity and Type 2 Diabetes Mellitus are important risk factors for a variety of malignancies. 
  • Latest studies show that diabetes increase the risk to develop up to 24 types of cancers. 
  • Diabetes patients are prone to develop up to 6 fold increase in specific cancers, including skin, pancreas, colon and liver cancer. 
  • Endogenous insulin treatment as well as diabetes drugs can increase cancer risk.
  • Diabetes patients respond more poorly to cancer therapy, which is associated with higher mortality.

Although the clinical significance is striking, the underlying mechanism was unknown – until now.

TenCure's exciting scientific data revealed, for the first time, the exact mechanism by which obesity and diabetes affect cancer formation and progression. Accordingly, TenCure develops drug candidates that block cancer cells physiology, inhibit cancer cell proliferation, and dramatically eradicate tumor formation and suppress tumor progression to malignancy. These breakthrough new technologies have been shown to be effective in vitro and in vivo in a variety of animal and human models.

TenCure’s breakthrough discovery, provides the basis for development of novel cancer therapies addressing various  solid cancers that are resistant to current treatment modalities, such as Skin Cancers, Lung, Colon and Pancreatic Cancers. Evidently, TenCure's technology can be integrated into the current emerging concept of target directed medicines where personalized treatment regimens are tailored to fit patient's tumor specific characteristics. 

In addition, our technological platform supports development of sensitive diagnostic markers for following cancer progression and therapeutic potential. 


Science and Technology